https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-04-12 / Cancer Immunol. Immunother. 2015 Jul;64(7):831-42
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-04-12 / Cancer Immunol. Immunother. 2015 Jul;64(7):831-422015-04-12 00:00:002019-02-15 08:45:10Engineering monocyte-derived dendritic cells to secrete interferon-α enhances their ability to promote adaptive and innate anti-tumor immune effector functions
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-04-02 / Science 2015 May;348(6236):803-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-04-02 / Science 2015 May;348(6236):803-82015-04-02 00:00:002019-02-15 08:49:36Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-03-27 / PLoS Pathog. 2015 Mar;11(3):e1004752
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-03-27 / PLoS Pathog. 2015 Mar;11(3):e10047522015-03-27 00:00:002019-02-15 08:48:01Decreased HIV-specific T-regulatory responses are associated with effective DC-vaccine induced immunity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-03-17 / Biol. Pharm. Bull. 2015;38(6):827-35
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-03-17 / Biol. Pharm. Bull. 2015;38(6):827-352015-03-17 00:00:002019-02-15 08:53:06Survivin and PSMA Loaded Dendritic Cell Vaccine for the Treatment of Prostate Cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-03-11 / Nature 2015 Mar;519(7543):300-1
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-03-11 / Nature 2015 Mar;519(7543):300-12015-03-11 00:00:002019-02-15 08:39:32Cancer immunotherapy: dendritic-cell vaccines on the move
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-03-10 / Oncotarget 2015 Mar;6(7):5195-203
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-03-10 / Oncotarget 2015 Mar;6(7):5195-2032015-03-10 00:00:002019-02-15 08:45:08A novel cancer immunotherapy based on the combination of a synthetic carbohydrate-pulsed dendritic cell vaccine and glycoengineered cancer cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-03-09 / Cancer Sci. 2015 Apr;106(4):397-406
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-03-09 / Cancer Sci. 2015 Apr;106(4):397-4062015-03-09 00:00:002019-02-15 08:52:27Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-03-04 / Tumour Biol. 2015 Mar;36(3):1411-22
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-03-04 / Tumour Biol. 2015 Mar;36(3):1411-222015-03-04 00:00:002019-02-15 08:45:39Immunotherapy for lung cancer: for whom the bell tolls?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-03-03 / Front Immunol 2015;6:91
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-03-03 / Front Immunol 2015;6:912015-03-03 00:00:002019-02-15 08:45:08Dendritic cell-based vaccine efficacy: aiming for hot spots
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-03-02 / Exp. Biol. Med. (Maywood) 2015 Oct;240(10):1310-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-03-02 / Exp. Biol. Med. (Maywood) 2015 Oct;240(10):1310-82015-03-02 00:00:002019-02-15 08:52:36Comparison of cytotoxic T lymphocyte responses against pancreatic cancer induced by dendritic cells transfected with total tumor RNA and fusion hybrided with tumor cell
